Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 2 Trials for Pembrolizumab (DB09037)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03248570Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair DefectsTreatment